18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation

Basit Öğe Kaydı
dc.contributor.authorKuyumcuoglu, Umur
dc.contributor.authorIrfan, Guzel Ali
dc.contributor.authorCelik, Yusuf
dc.contributor.authorErdemoglu, Mahmut
dc.contributor.authorKomek, Halil
dc.date.accessioned2024-04-24T17:33:09Z
dc.date.available2024-04-24T17:33:09Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: The role of F-18-FDG (F-18 fluorodeoxyglucose) PET/CT** (Positron emission tomography) in the diagnosis, treatment and follow up of benign and malignant ovarian tumors had been investigated previously. The objective of the following study was to evaluate the predictive value of PET/CT in benign and malignant ovarian tumors and compare with computerized tomography and post-operative pathology. Materials and methods: In this retrospective study a total of sixty nine cases with benign or malignant pelvic masses underwent laparotomy at our clinic. Postoperative pathology of the patients was recorded and PET/CT results were compared with ultrasonography, computerized tomography and postoperative pathology. Results: The ROCs and AUCs values four predictors were shown in Figure 1. The AUCs (95 % CI) values calculated for CA 125, ultrasonography (USG), PET/CT and CT were as follows: 0.855(0.752-0.958), 0.703(0.540-0.866), 0.681(0.514-0.848) and 0.631(0.463-0.799) respectively. CA 125 has the highest AUC value in order to predict the malignant potential of the patient. USG has the highest AUC value between the imaging techniques, following PET/CT and CT. Conclusion: According to this study among four modalities that distinguish malignant potential preoperatively; CA 125 is the best parameter. USG and PET provide similar benefits in detecting malignant ovarian masses preoperatively. Both of these parameters are superior to CT. Combination of CA 125, USG and PET/CT may be useful in detecting malignant ovarian masses preoperatively, resulting in less invasive surgeries. **F-18-FDG (F-18 fluorodeoxyglucose) PET/CT will be used as the PET/CT, later in this article.en_US
dc.identifier.endpage606en_US
dc.identifier.issn0017-0011
dc.identifier.issue8en_US
dc.identifier.pmid21957605
dc.identifier.scopus2-s2.0-80054844481
dc.identifier.scopusqualityQ3
dc.identifier.startpage602en_US
dc.identifier.urihttps://hdl.handle.net/11468/20482
dc.identifier.volume82en_US
dc.identifier.wosWOS:000293870500007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherStudio Ken_US
dc.relation.ispartofGinekologia Polska
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPet/Cten_US
dc.subjectBenign Ovarian Tumorsen_US
dc.subjectMalignant Ovarian Tumorsen_US
dc.subjectPredictive Value Of Testsen_US
dc.title18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlationen_US
dc.title18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu